Grupo Galego de Investigaciones Oncolóxicas
GIO
Hospital Universitario La Paz
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario La Paz (24)
2023
-
Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease
Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167
2019
-
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group
British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807
2017
-
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma
Blood
-
The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways
Scientific Reports, Vol. 7
-
Whole Exome Sequencing reveals new candidate genes in host genomic susceptibility to Respiratory Syncytial Virus Disease
Scientific Reports, Vol. 7, Núm. 1
2016
-
Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial
Annals of Hematology, Vol. 95, Núm. 6, pp. 893-899
-
Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients
Acta Haematologica, Vol. 136, Núm. 2, pp. 76-84
2015
-
Chronic lymphocytic leukemia cells in lymph nodes show frequent NOTCH1 activation
Haematologica, Vol. 100, Núm. 5, pp. e200-e203
-
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations
Leukemia Research Reports, Vol. 4, Núm. 2, pp. 64-69
-
Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations
International Journal of Cancer, Vol. 137, Núm. 8, pp. 1870-1878
2014
-
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosaassociated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial
The Lancet Haematology, Vol. 1, Núm. 3, pp. e104-e111
-
GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: Do we still need alkylators?
Blood, Vol. 124, Núm. 12, pp. 1887-1893
-
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: A phase II GELTAMO trial
British Journal of Haematology, Vol. 167, Núm. 3, pp. 327-336
-
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation
Leukemia, Vol. 28, Núm. 6, pp. 1334-1340
2013
-
Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Nuclear Medicine Communications, Vol. 34, Núm. 10, pp. 946-952
2012
-
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial
Blood, Vol. 120, Núm. 13, pp. 2581-2588
2011
-
Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study
Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2
2010
-
Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial
The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941
1998
-
Autotransplantation in chronic myeloid leukemia [1]
Bone Marrow Transplantation
1997
-
Autologous transplantation of peripheral stem cells in patients with chronic myeloid leukemia after mobilization with high-dose hydroxyurea
Sangre, Vol. 42 Suppl 1, pp. 21-23